Monopar Therapeutics (MNPR) Stock Takes a Dive After Wilson Disease Licensing Deal
Monopar Therapeutics (MNPR) shares are facing a significant drop on Friday, following a surge in value the day before. The company’s stock price volatility stems from a recent licensing agreement with Alexion, AstraZeneca Rare Disease, for the exclusive worldwide rights to ALXN-1840, a drug potentially treating Wilson disease.
The drug has demonstrated potential in a Phase 3 clinical trial, successfully meeting its primary endpoint. However, Alexion previously discontinued the ALXN-1840 program in 2023 based on data from Phase 2 trials and guidance from regulatory authorities. Monopar will now take the reins for all future development and commercialization initiatives for ALXN-1840.
As part of the agreement, Monopar will make an upfront cash payment to Alexion and grant them equity in Monopar. Future payments will be structured based on tiered royalties on net sales and established regulatory and sales milestones.
“We are thrilled to partner with Alexion and AstraZeneca as they have a significant presence in the radiopharma field, which aligns with Monopar’s growth strategy,” said Andrew Cittadine, COO of Monopar, referencing their recent positive human clinical data with their novel radiopharma program. “This partnership strengthens our commitment to advancing innovative treatments in this area.”
How to Invest in Monopar Stock
The recent market activity surrounding Monopar has likely piqued the interest of investors. If you’re considering investing in Monopar Therapeutics, you can typically purchase shares through a brokerage account. There are many reputable online trading platforms available, offering the convenience of buying fractional shares, which allows you to own portions of stock without purchasing an entire share. This can be particularly useful when dealing with stocks like Berkshire Hathaway, where owning a single share can be quite expensive.
For those seeking to bet against the company’s stock performance, the process is more complex. You’ll need access to an options trading platform or a broker who allows short-selling. Shorting a stock involves borrowing shares from a broker and selling them immediately, hoping to repurchase them at a lower price later to profit from the difference. This is a risky strategy, and you should thoroughly research and understand the risks before attempting to short any stock.
MNPR Price Action
As of the time of writing, Monopar shares are trading 38.9% lower, reaching $19.95, according to data from Benzinga Pro.
This article is for informational purposes only and should not be considered as investment advice.
